Johnson & Johnson’s $4.5 Billion Registered Notes Offering
November 15, 2017
Cravath represented the underwriters, led by Bank of America Merrill Lynch, Goldman Sachs & Co. LLC, J.P. Morgan Securities, Citigroup and Deutsche Bank Securities, in connection with the $4.5 billion registered notes offering of Johnson & Johnson, a company engaged in the research and development, manufacturing and sale of a broad range of products in the healthcare field. The transaction closed on November 10, 2017.
The Cravath team included partner Craig F. Arcella and associate Alexander E. Shiekman. Katharine A. Patterson also worked on this matter.
Related Practices & Industries
People
- Photo
-
-
J.D., 1998, Columbia Law SchoolHarlan Fiske Stone Scholar
-
B.A., 1995, Duke University
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
March 12, 2025
Johnson & Johnson’s $5 Billion Registered Notes Offering and Concurrent €4 Billion Notes Offering
Cravath represented the underwriters in connection with the $5 billion registered notes offering of Johnson & Johnson, the world’s largest, most diversified healthcare products company. Cravath also represented the underwriters in connection with Johnson & Johnson’s concurrent €4 billion notes offering. Proceeds of both offerings will be used to finance the acquisition of Intra‑Cellular Therapies, Inc. by Johnson & Johnson. The transactions closed on February 20, 2025, and February 26, 2025, respectively.
